🔎 Trials Near Me

Home › Hidradenitis Suppurativa

Hidradenitis Suppurativa clinical trials recruiting in the U.S.

30 studies for Hidradenitis Suppurativa are recruiting participants at sites across the United States.

Hidradenitis suppurativa (HS), or acne inversa, is a chronic skin disease. It causes painful bumps in your armpits and groin. Learn about treatment.

Cities with the most studies

By state

Recently updated studies

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT06855498

A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS

RecruitingPhase 1
Ages 18 to 65 · All sexes · Updated Nov 10, 2026 · NCT07855276

An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Nov 9, 2026 · NCT07665437

ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa

RecruitingPhase 2
Ages 18 to 79 · All sexes · Updated Oct 29, 2026 · NCT07783542

A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)

RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Oct 19, 2026 · NCT07766005

A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 16, 2026 · NCT07225569

Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT07828860

Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa

RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT07170917

Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa

RecruitingPhase 2
Ages 12 and older · All sexes · Updated Oct 13, 2026 · NCT07689188

Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

RecruitingPhase 1
Ages 12 to 75 · All sexes · Updated Oct 9, 2026 · NCT07049575

Regulation of Inflammatory Genes in Hidradenitis Suppurativa

RecruitingObservational study
Ages 18 to 89 · All sexes · Updated Sep 21, 2026 · NCT05507125

Targeting Nociceptors in Hidradenitis Suppurativa

RecruitingObservational study
Ages 18 to 75 · All sexes · Updated Sep 10, 2026 · NCT05403710

Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa

RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06058520

Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.

RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Sep 1, 2026 · NCT06326476

A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa

RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Jul 22, 2026 · NCT07384975

Myriad™ Augmented Soft Tissue Reconstruction Registry

RecruitingObservational study
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT05243966

The Safety and Efficacy of Roflumilast Foam in HS

RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 9, 2026 · NCT07263230

Pelashield™ PainGuard™ vs Restrata® in HS Surgery

Recruiting
Ages 18 and older · All sexes · Updated May 22, 2026 · NCT07316192

Radiotherapy for Refractory Hidradenitis Suppurativa

Recruiting
Ages 18 and older · All sexes · Updated May 15, 2026 · NCT07414550

Clinical and Biological Characteristics of Hidradenitis Suppurativa

RecruitingObservational studyHealthy volunteers welcome
Ages 13 and older · All sexes · Updated May 4, 2026 · NCT03967600

Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository

RecruitingObservational study
Ages 10 and older · All sexes · Updated Apr 29, 2026 · NCT04115566

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.